First Header Logo Second Header Logo

Connection

Thomas Wierzba to Escherichia coli Infections

This is a "connection" page, showing publications Thomas Wierzba has written about Escherichia coli Infections.
Connection Strength

3.408
  1. Barry E, Cassels F, Riddle M, Walker R, Wierzba T. Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Vaccine. 2019 08 07; 37(34):4768-4774.
    View in: PubMed
    Score: 0.655
  2. Wierzba TF. Implications and measurement of herd protection (indirect effects) for enteric vaccine development. Vaccine. 2019 08 07; 37(34):4775-4777.
    View in: PubMed
    Score: 0.655
  3. Wierzba TF, Bourgis A. Defining cases of severe pediatric diarrhea for an efficacy trial of an enterotoxigenic Escherichia coli (ETEC) vaccine: Report on an international workshop, Washington DC, March 2016. Vaccine. 2017 01 23; 35(4):503-507.
    View in: PubMed
    Score: 0.547
  4. Ahmed SF, Shaheen HI, Abdel-Messih IA, Mostafa M, Putnam SD, Kamal KA, Sayed AN, Frenck RW, Sanders JW, Klena JD, Wierzba TF. The epidemiological and clinical characteristics of diarrhea associated with enteropathogenic, enteroaggregative and diffuse-adherent Escherichia coli in Egyptian children. J Trop Pediatr. 2014 Oct; 60(5):397-400.
    View in: PubMed
    Score: 0.464
  5. Bagamian KH, Anderson JD, Muhib F, Cumming O, Laytner LA, Wierzba TF, Rheingans R. Heterogeneity in enterotoxigenic Escherichia coli and shigella infections in children under 5 years of age from 11 African countries: a subnational approach quantifying risk, mortality, morbidity, and stunting. Lancet Glob Health. 2020 01; 8(1):e101-e112.
    View in: PubMed
    Score: 0.167
  6. Anderson JD, Bagamian KH, Muhib F, Amaya MP, Laytner LA, Wierzba T, Rheingans R. Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis. Lancet Glob Health. 2019 03; 7(3):e321-e330.
    View in: PubMed
    Score: 0.159
  7. Akhtar M, Chowdhury MI, Bhuiyan TR, Kaim J, Ahmed T, Rafique TA, Khan A, Rahman SIA, Khanam F, Begum YA, Sharif MZ, Islam LN, Carlin N, Maier N, Fix A, Wierzba TF, Walker RI, Bourgeois AL, Svennerholm AM, Qadri F, Lundgren A. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses. Vaccine. 2019 09 03; 37(37):5645-5656.
    View in: PubMed
    Score: 0.156
  8. Walker RI, Wierzba TF, Mani S, Bourgeois AL. Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine. 2017 12 14; 35(49 Pt A):6775-6782.
    View in: PubMed
    Score: 0.144
  9. Bourgeois AL, Wierzba TF, Walker RI. Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine. 2016 06 03; 34(26):2880-2886.
    View in: PubMed
    Score: 0.129
  10. Desai SN, Sahastrabuddhe S, Ochiai RL, Wierzba TF. Enteric vaccines for resource-limited countries: current status and future prospects. Pediatr Ann. 2011 Jul; 40(7):351-7.
    View in: PubMed
    Score: 0.093
  11. Rao MR, Wierzba TF, Savarino SJ, Abu-Elyazeed R, El-Ghoreb N, Hall ER, Naficy A, Abdel-Messih I, Frenck RW, Svennerholm AM, Clemens JD. Serologic correlates of protection against enterotoxigenic Escherichia coli diarrhea. J Infect Dis. 2005 Feb 15; 191(4):562-70.
    View in: PubMed
    Score: 0.060
  12. Shaheen HI, Khalil SB, Rao MR, Abu Elyazeed R, Wierzba TF, Peruski LF, Putnam S, Navarro A, Morsy BZ, Cravioto A, Clemens JD, Svennerholm AM, Savarino SJ. Phenotypic profiles of enterotoxigenic Escherichia coli associated with early childhood diarrhea in rural Egypt. J Clin Microbiol. 2004 Dec; 42(12):5588-95.
    View in: PubMed
    Score: 0.059
  13. Clemens J, Savarino S, Abu-Elyazeed R, Safwat M, Rao M, Wierzba T, Svennerholm AM, Holmgren J, Frenck R, Park E, Naficy A. Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. J Infect Dis. 2004 Jun 15; 189(12):2299-307.
    View in: PubMed
    Score: 0.057
  14. Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF, Abu-Elyazeed R, Rao M, Francis WM, El Mohamady H, Safwat M, Naficy AB, Svennerholm AM, Jertborn M, Lee YJ, Clemens JD. Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J. 2002 Apr; 21(4):322-30.
    View in: PubMed
    Score: 0.049
  15. Rao MR, Abu-Elyazeed R, Savarino SJ, Naficy AB, Wierzba TF, Abdel-Messih I, Shaheen H, Frenck RW, Svennerholm AM, Clemens JD. High disease burden of diarrhea due to enterotoxigenic Escherichia coli among rural Egyptian infants and young children. J Clin Microbiol. 2003 Oct; 41(10):4862-4.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.